T-DM1 was subsequently approved in 2019 as adjuvant therapy for the treatment of HER2-positive early BC in patients with residual invasive disease following taxane (mitotic inhibitor)-based chemotherapy and trastuzumab treatment [93]. The gene discussed is ERBB2; the disease is breast cancer.